Amylyx Pharmaceuticals, Inc.
AMLX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001658551
In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.
Superinvestors holding AMLX, Q2 2026
No superinvestor reported holding AMLX in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of AMLX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2024
0 superinvestors holding at quarter end
- Sold out
- Viking Global Investors
Q1 2023
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−36.1%)
Q4 2022
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−19.7%)
Q3 2022
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−19.5%)
Q1 2022
1 superinvestor holding at quarter end